Clinical trial
Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy
NCT00366080 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00366080 |
|---|---|
| Title | Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy |
| Official title | An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Narcolepsy |
| Intervention type | Drug |
| Interventions | GSK189254 |
| Enrollment | 69 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Aug 18, 2006 |
| Last update posted | Mar 10, 2017 |
| Countries | Austria, Finland, Germany, Netherlands, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: